Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Silo Pharma ( (SILO) ) is now available.
On February 20, 2026, Silo Pharma entered into an addendum to its service agreement with an investor relations consultant, agreeing to pay a $250,000 commitment fee in company stock rather than cash. The fee, calculated at the Nasdaq minimum price of $0.2947 per share on the signing date, resulted in the issuance of 848,320 common shares with no cash proceeds to the company, under a private placement exemption.
On February 23, 2026, the company’s board approved a stock repurchase program authorizing buybacks of up to $1 million of common stock, which may be executed in the open market or through private transactions subject to regulatory constraints. The discretionary buyback, coming as Silo previously reported 13.3 million shares outstanding as of November 13, 2025, signals management’s view that current market conditions undervalue the shares and represents a capital allocation move aimed at enhancing shareholder value.
More about Silo Pharma
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on merging traditional therapeutics with psychedelic research. Its pipeline targets underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, including programs SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets in Alzheimer’s disease and multiple sclerosis, developed in collaboration with universities and laboratories.
Average Trading Volume: 182,479
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.9M
For detailed information about SILO stock, go to TipRanks’ Stock Analysis page.